Abstract-Both angiotensin II (Ang II) and transforming growth factor (TGF)-␤1 are thought to be involved in the progression of chronic kidney disease. In contrast, hepatocyte growth factor (HGF) counteracts the actions of Ang II and TGF-␤1. Therefore, in this study, we investigated the molecular mechanisms of how HGF antagonizes the Ang II-TGF-␤ axis in renal cells. In cultured human mesangial cells, TGF-␤1 increased angiotensin type 1 receptor (AT 1 R) mRNA, mainly dependent on the Akt/phosphatidylinositol 3-kinase signaling pathway. Furthermore, TGF-␤1 decreased the expression and phosphatase activity of phosphatase and tensin homolog, deleted on chromosome 10 (PTEN), a negative regulator of the phosphatidylinositol 3-kinase/Akt pathway. These data revealed positive feedback of the Ang II-TGF-␤ pathway, because Ang II increased TGF-␤ expression. In contrast, HGF significantly attenuated the increase in AT 1 R gene expression, and inhibited the decrease in PTEN induced by TGF-␤1. Of importance, a PTEN-specific inhibitor significantly attenuated the reduction in TGF-␤1-induced AT 1 R expression by HGF. These data suggest that HGF attenuated TGF-␤1-induced AT 1 R expression through the PTEN/Akt pathway. To investigate this hypothesis, we performed in vivo experiments in mice with increased circulating levels of HGF produced by transgenically expressing HGF under control of a cardiac-specific transgene (HGF-Tg). In HGF-Tg mice, renal injury and fibrosis were significantly decreased, associated with reduction in AT 1 R expression and increase in PTEN after Ang II infusion, as compared with control mice. Moreover, these renal protective effects were abrogated by a neutralizing antibody against HGF. Thus, the present study demonstrated that HGF counteracts the vicious cycle of Ang II-TGF-␤1-AT 1 R, mediating the inhibition of PTEN. 
M
aladaptive activation of the renin-angiotensin system (RAS) has been shown to play a pivotal role in the pathogenesis of chronic kidney disease (CKD). Angiotensin II (Ang II), the major bioactive peptide of RAS, is a potent systemic vasoconstrictor and modulator of the renal circulation. Ang II has important nonhemodynamic effects that have been implicated in the pathogenesis of CKD by promoting mesangial cell hypertrophy and proliferation, increasing extracellular matrix synthesis 1 and promoting inflammation. 2 The biological responses to Ang II are mediated by 2 plasma membrane receptors, Ang II type 1 receptor (AT 1 R) and Ang II type 2 receptor. 3 Most of the known pathophysiological effects of Ang II are mediated by AT 1 R. In both clinical and experimental studies, angiotensin-converting enzyme (ACE) inhibitors and Ang II type I receptor blockers (ARBs) clearly revealed renoprotective effects. In contrast, transforming growth factor-␤ (TGF-␤) is also well known to be a key mediator in the progression of CKD. TGF-␤1 has been linked mainly to fibrinogenesis in some animal models. One of the striking effects of TGF-␤1 is stimulation of AT 1 R expression, whereas the proatherosclerotic action of Ang II is mediated, at least in part, by TGF-␤1. Thus, the positive feedback loop of Ang II and TGF-␤1 might result in amplification of their profibrotic effects in renal cells.
In contrast, hepatocyte growth factor (HGF) is a pleiotropic factor that plays an essential role in the regulation of cell proliferation, survival, and differentiation in a variety of organs. Specifically, HGF prevented renal interstitial fibrosis in several animal models of CKD. Recent studies suggest that HGF counteracts the action of TGF-␤1 in different types of kidney cells, resulting in inhibition of TGF-␤-mediated myofibroblastic activation of glomerular mesangial cells and interstitial fibroblasts and blockade of tubular epithelial-tomesenchymal transition. In general, it is believed that HGF antagonizes the profibrotic actions of TGF-␤1 by intercepting Smad signal transduction in different kidney cells and the injured kidney. 4 In addition, our group demonstrated recently that HGF promoted apoptosis of myofibroblasts, an important source of TGF-␤1. 5 However, the molecular mechanisms of inhibition of the Ang II-TGF␤ pathway by HGF have not been fully clarified. Thus, in this study, we investigated how HGF counteracts the positive feedback loop between Ang II and TGF-␤1 that results in amplification of their profibrotic effects in the kidney.
Materials and Methods
Please see the online Data Supplement (http://hyper.ahajournals.org) for information on the primary antibodies and reagents used in the study.
In Vitro Experiments
Human mesangial cells were cultured in mesangial cell basic culture medium plus 5% FBS. The cells were seeded to 70% to 80% confluence in complete medium and then changed to serum-free medium. Recombinant human TGF-␤1 was added to the cultures at a final concentration of 1 ng/mL.
Western Blot Analysis and Quantitative Real-Time PCR
Preparation of protein extract and Western blotting were performed as described previously. 6 Total RNA was isolated as described previously. 6 In each experiment, mouse ␤-actin RNA was amplified as a reference standard.
In Vivo Experiments
We generated mice (C57BL6 background) with cardiac-specific (␣-major histocompatibility complex-driven) overexpression of HGF in which serum HGF derived from the heart was significantly increased. 7 We administrated Ang II (0.7 mg/kg per day) by using osmotic minipump (DURECT Corporation, Cupertino, CA) to HGFtransgenic (Tg) mice and C57BL6N mice (littermates) aged 8 to 10 weeks for 4 weeks. Blood pressure was measured by tail-cuff plethysmography. Mice were divided into 4 groups: (1) wild-type control mice treated with Ang II; (2) wild-type control mice treated with Ang II and hydralazine (30 mg/kg per day); (3) HGF-Tg mice treated with Ang II; and (4) HGF-Tg mice treated with Ang II and HGF neutralizing antibody (200 g/wk). Mice were euthanized at 4 weeks after Ang II infusion. All of the procedures were performed in accordance with the Osaka University School of Medicine Institutional Animal Committee.
Statistical Analysis
Values are expressed as meanϮSE. ANOVA and t test followed by Bonferroni adjustment for multiple comparisons were used for comparisons of Ͼ2 groups. A P value Ͻ0.05 was considered to indicate significance of difference of mean values.
Results

Role of Phosphatase and Tensin Homolog, Deleted on Chromosome 10 (PTEN) in Inhibition of AT 1 R Expression by HGF
To elucidate the molecular mechanisms of renal injury by Ang II, we first tested the effect of TGF-␤1 on AT 1 R mRNA expression in human mesangial cells, because our previous study demonstrated that Ang II stimulated TGF-␤1 mRNA expression in human mesangial cells. 5 As shown in Figure S1 (available in the online Data Supplement), TGF-␤1 significantly stimulated the expression of AT 1 R mRNA in a time-dependent manner from 1 to 24 hours (PϽ0.01). In contrast, Ang II stimulation alone did not change AT 1 R mRNA expression ( Figure 1A ). Of importance, pretreatment with HGF significantly attenuated the increase in AT 1 R mRNA expression induced by TGF-␤1 ( Figure 1A ). Our previous study demonstrated that pretreatment with HGF significantly decreased the increase in TGF-␤1 expression induced by Ang II 5 ; HGF attenuated the signal through the positive loop of the Ang II-TGF-␤1-AT 1 R axis. Although the main pathway of TGF-␤1 is the Smad pathway, recent studies revealed other pathways, such as phosphatidylinositol 3-kinase (PI3K), extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase, and c-Jun N-terminal kinase pathways, as either mediators or modulators of TGF-␤1-dependent biological effects. 8, 9 Our present data demonstrated that inhibition of PI3K (by LY294002) completely attenuated TGF-␤1-induced AT 1 R gene expression ( Figure  1B ), whereas inhibition of c-Jun N-terminal kinase (by SP600125) partially attenuated it. In contrast, inhibition of 
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HGF Downregulates AT 1 R Through PTEN/Akt Pathwayextracellular signal-regulated kinase 1/2 (by PD98059) and p38 (by SB203580) did not affect it, indicating that the increase in AT 1 R expression induced by TGF-␤1 might be mainly through the PI3K-Akt signaling pathway. Therefore, we focused on the HGF-PI3K/Akt pathway. TGF-␤1 significantly increased the phosphorylation of Akt, which was maximal at 15 minutes (data not shown). However, pretreatment with HGF significantly attenuated Akt phosphorylation stimulated by TGF-␤1 (Figure 2A and 2B ; PϽ0.01). Because PI3K action is regulated by the tumor suppressor protein, phosphatase and tensin homolog, deleted on chromosome 10 (PTEN), by dephosphorylation of phosphatidylinositol (PI) 3,4,5-trisphosphate, 10, 11 we next focused on the role of PTEN. Interestingly, as shown in Figure S2A , TGF-␤1 significantly decreased the expression of PTEN in a time-dependent manner, whereas HGF markedly attenuated the decrease in PTEN expression induced by TGF-␤1 ( Figure  S2B ; PϽ0.01). Of importance, a PTEN inhibitor (bpV[OH]pic) significantly inhibited the attenuation of TGF-␤1-induced Akt activation by HGF (Figure 2A and 2B ; PϽ0.01). To elucidate the role of PTEN in the increase in AT 1 R expression induced by TGF-␤1, we further studied the effects of a PTEN inhibitor on AT 1 R expression. Of importance, as shown in Figure 2C , the addition of a PTEN inhibitor significantly prevented the decrease in TGF-␤1-induced AT 1 R expression by HGF (PϽ0.01). Furthermore, to determine by which mechanism HGF controls PTEN synthesis, luciferase reporter constructs encoding the PTEN promoter were used. TGF-␤1 significantly reduced PTEN reporter gene activity, whereas this effect was blocked by HGF treatment ( Figure S3 ), suggesting that HGF regulated TGF-␤1-induced PTEN transcriptional downregulation. These data indicated that HGF inhibited TGF-␤1-induced AT 1 R expression via the Akt-PTEN pathway.
Overexpression of HGF Inhibited Renal Damage Induced by Ang II Infusion in HGF-Tg Mice
To further confirm the in vitro findings, we used an in vivo model of Ang II infusion into mice, which exhibited severe renal damage. Our present data confirmed renal injury, such as fibrosis, by Ang II infusion (Figure 3) . Because HGF is a renal protective growth factor, we used transgenic mice with cardiac-specific overexpression of human HGF (HGF-Tg). These HGF-Tg mice showed a significant increase in the serum human HGF concentration of Ϸ3-fold as compared with control littermates. 7 As expected, HGF-Tg mice exhibited a much lower degree of renal injury, as assessed by diameter of the glomerulus, and glomerular injury index ( Figure 3A through 3C, PϽ0.01, respectively) . Similarly, HGF-Tg mice exhibited significantly less renal fibrosis as compared with control ( Figure 3D and 3E, PϽ0.01 ). Although there was no significant difference in systolic blood pressure (SBP) between HGF-Tg and wild-type mice at baseline (SBP: 100.1Ϯ2.8 versus 104.8Ϯ5.8 mm Hg, respectively), SBP was significantly lower in HGF-Tg mice than in control littermates after 3 weeks of Ang II infusion ( Figure  S4 ; SBP: 104.2Ϯ3.1 versus 120.1Ϯ1.0 mm Hg, respectively; PϽ0.05). Thus, to examine whether the prevention of renal fibrosis in HGF-Tg mice could be attributed to the reduction in BP, we further examined the effects of hydrazine, an antihypertensive drug, on fibrosis. Although treatment with hydralazine significantly decreased SBP and DBP as compared with vehicle treatment ( Figure S4 ; SBP: 120.1Ϯ1.8 versus 107.3Ϯ4.1 mm Hg; DBP: 79.2Ϯ4.7 versus 69.7Ϯ4.2 mm Hg; PϽ0.05, respectively), there were no significant differences in the diameter of glomeruli and glomerular injury index between control and hydralazinetreated animals ( Figure 3 ). These data indicate that reductions in blood pressure alone may not be sufficient to account for the renal protective effects of HGF. To further explore the role of HGF in renal protection, we administered a neutralizing antibody against HGF to HGF-Tg mice treated with Ang II. At baseline, there was no difference in SBP between those with or without neutralizing antibody against HGF in HGF-Tg mice (100.1Ϯ2.8 versus 99.8Ϯ1.8 mm Hg, respectively). As shown in Figure 3 , the renal protective effect in HGF-Tg mice was significantly inhibited by neutralizing anti-HGF antibody (Figure 3A through 3C; PϽ0.01) . Similarly, renal fibrosis was significantly inhibited in HGF-Tg mice as compared with control, whereas administration of neutralizing anti-HGF antibody attenuated the renal protective action in HGF-Tg mice (Figure 3D and 3E; PϽ0.01 ). Interestingly, Ang II infusion into control mice significantly increased the expression of renal AT 1 R mRNA as determined by quantitative PCR analyses ( Figure 4A ; PϽ0.05). In contrast, renal AT 1 R mRNA induced by Ang II infusion was significantly lower in HGF-Tg mice ( Figure 4A ; PϽ0.05). Because our previous report demonstrated that TGF-␤1 mRNA expression was significantly lower in HGF-Tg mice as compared with control, 5 we hypothesized that HGF might affect PTEN expression and Akt phosphorylation in the kidney, because PTEN attenuated Akt phosphorylation. As shown in Figure 4B , Ang II infusion to control mice induced a marked decrease in the level of PTEN and an increase in the level of Akt phosphorylation. However, in HGF-Tg mice treated with Ang II, PTEN gradually increased and Akt phosphorylation decreased. The contribution of HGF was confirmed by the observation that treatment with neutralizing antibody against HGF significantly decreased the increase in PTEN expression (Figure 5A and 5B; PϽ0.05). Importantly, neutralizing anti-HGF antibody significantly increased AT 1 R expression induced by Ang II, whereas AT 1 R expression induced by HGF was significantly lower in HGF-Tg mice as compared with control ( Figure 5C ; PϽ0.05).
Discussion
Mesangial cells are the major cells involved in the development of CKD. Ang II regulates mesangial cell hypertrophy and increases the expression and synthesis of ECM. Indeed, it is well known that blockade of the activation of RAS by ACE inhibitors and ARBs preserved or improved renal function in numerous clinical studies. Another important player related to CKD is TGF-␤1, which is mainly involved in the progression of glomerulosclerosis. Thus, researchers tried to elucidate the relation between Ang II and TGF-␤. In mesangial cells, Ang II increased TGF-␤1 mRNA expression, whereas a neutralizing antibody against TGF-␤ significantly reduced ECM production induced by Ang II. 12 Furthermore, previous reports showed that ARBs inhibited the expression of TGF-␤1. [13] [14] [15] The present study demonstrated that TGF-␤1 increased the expression of AT 1 R, suggesting positive feedback of Ang II-TGF-␤ by which Ang II increased TGF-␤, the induced TGF-␤ expression stimulated AT 1 R expression, and upregulation of AT 1 R enhanced Ang II signaling ( Figure S5 ). To clarify this complicated pathway, we focused on PTEN, because PTEN protein is a phosphatidylinositol phosphate phosphatase specific for the 3-position ring. Although PTEN can dephosphorylate PI3P, PI(3,4)P2, and PI(3,4,5)P3, it is likely that PI(3,4,5)P3 level in the plasma membrane decreases, which, in turn, regulates Akt kinase. Furthermore, a change in expression and activation of PTEN is involved in the pathophysiology of various diseases, such as pulmonary fibrosis. 16 Moreover, PTEN acts as a negative regulator of myofibroblast, a major source of TGF-␤1. The present study clearly demonstrated that the missing link in the Ang II-TGF-␤ pathway is PTEN/Akt.
Interestingly, one of the most well-known factors antagonizing TGF-␤ is HGF. Currently, HGF is reported to counteract the profibrotic action of TGF-␤1 by intercepting Smad signaling through different mechanisms in various types of kidney cells. 4 For example, in human mesangial cells, HGF signaling stabilizes the Smad transcriptional corepressor TGF-␤-induced factor homeobox 1 (TGIF) against degradation. Accumulated TGIF binds to Smads and sequesters their ability to initiate the transcription of TGF-␤1 target genes. 17 In addition, our recent study demonstrated that HGF induced apoptosis of myofibroblasts, associated with an increase in MMPs expression and a decrease in ECM, potentially because of inhibition of TGF-␤1 signaling. 5, 18, 19 In addition to these known mechanisms, the present study suggests a novel pathway through the PI3K-Akt/PTEN pathway. HGF plays the role of antiapoptotic effect, mediating the activation of Akt/ PI3K pathway. 20 However, our present data showed that pretreatment with HGF decreased TGF-␤1-induced Akt phosphorylation. In addition, some groups, other than ours have reported that HGF has antiapoptotic effects on endothelial cells. 21, 22 On the other hand, HGF induced apoptotic cell death in some distinct types of cells, including transformed or neoplastic cells 23 and myofibroblasts. 5, 18, 19 It might be a reason that HGF biologically regulates cell survival in a cell type-dependent manner. Furthermore, our recent study reported that HGF promotes oxidative stress in cultured endothelial cells but inhibits Ang II-induced excess oxidative stress thorough an epidermal growth factor receptor degradation mechanism. 24 These results suggest that it might be different from the expression levels of c-Met, because local HGF is thought to be commonly decreased on pathological conditions. However, further studies are necessary to reveal the role of the c-Met/HGF system.
Here, we demonstrated that HGF inhibited the increase in AT 1 R expression by TGF-␤1 by inhibition of phosphorylation of Akt through upregulation of PTEN. Not only in vitro experiments but also in vivo studies using HGF-Tg mice demonstrated that HGF inhibited the increase in AT 1 R expression by Ang II through the PI3K-Akt/PTEN pathway. From the clinical view points, it is noteworthy that ACE inhibitors and ARBs significantly increased local HGF expression in the heart, kidney, and other organs in various models. [25] [26] [27] Our present data demonstrated that reductions in blood pressure alone may not be sufficient to account for the renal protective effects of HGF. Because ARBs and ACE inhibitors, which are known to increase local HGF expression, have pleiotropic effects beyond blood pressure control, 28 the increase in local HGF expression by ARBs or ACE inhibitors might contribute to those pleiotropic effects. In fact, we confirmed that telmisartan, one of the ARBs that have the characteristics of a partial agonist of peroxisome proliferator-activated receptors, induced HGF expression in rat mesangial cells (data not shown).
Overall, the present study revealed novel molecular mechanisms of the inhibition of the Ang II-TGF-␤-positive feedback system by HGF, which was related to the PI3K-Akt/ PTEN pathway. The increase in local HGF by blockade of RAS might contribute to the clinical benefits of ARBs and ACE inhibitors in CKD. A clinical trial of recombinant HGF to prevent renal injury is now underway. Further development of pharmacotherapy to stimulate HGF, together with RAS inhibition, might improve CKD.
Perspectives
CKD is an independent risk factor for cardiovascular events and outcomes. Conversely, cardiovascular diseases are asso- ciated independently with CKD. Recently, the concept of the cardiorenal syndrome has been spreading. Fortunately, the importance of the cardiorenal syndrome has recently been realized, and researchers are looking at both the cause and treatment. 29 Currently, therapy for chronic renal fibrosis is quite limited, despite the introduction of ACE inhibitors and ARBs into standard medical therapy. Ang II blockade alone is not sufficient to prevent CKD. Importantly, combined therapy with HGF and ARB would result in a synergistic, marked attenuation of renal fibrosis. 30 Furthermore, our group and others showed an antifibrotic effect of HGF on not only renal fibrosis but also cardiac fibrosis. 25, 31 Activation of the HGF system might thus be a new potential therapy to prevent the cardiorenal syndrome.
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